Literature DB >> 30853252

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox.

Kirk M Chan-Tack1, Patrick R Harrington2, Su-Young Choi3, Laine Myers2, Julian O'Rear2, Shirley Seo3, David McMillan2, Hanan Ghantous2, Debra Birnkrant2, Adam I Sherwat2.   

Abstract

The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule. We summarise the regulatory pathway and describe the challenges involved.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30853252     DOI: 10.1016/S1473-3099(18)30788-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  2 in total

1.  Can a smallpox drug treat monkeypox? Compassionate use of tecovirimat for monkeypox infection.

Authors:  Maurish Fatima; Aleena Ahmed; Muhammad Wahaj Murad; Zeeshan Afzal
Journal:  Eur J Intern Med       Date:  2022-09-21       Impact factor: 7.749

Review 2.  Monkeypox virus: past and present.

Authors:  Ya-Mei Dou; Hang Yuan; Hou-Wen Tian
Journal:  World J Pediatr       Date:  2022-10-10       Impact factor: 9.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.